Updated result from the phase 2 PHAROS study: has the sustained efficacy and tolerability of encorafenib plus binimetinib been demonstrated in patients with <i>BRAF</i> V600E-mutant metastatic non-small-cell lung cancer?

ABSTRACT:

SUBMITTER: Yonesaka K 

PROVIDER: S-EPMC12780439 | biostudies-literature | 2025 Dec

REPOSITORIES: biostudies-literature